ANIMATION

HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO

Client


PDL BioPharma

Working with XVIVO was an excellent choice, we are so happy with the finished animation. It was particularly satisfying showing it to the executive team and hearing, ‘it looks marvelous’.

Senior Researcher, FrieslandCampina